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ABSTRACT 
EVALUATION OF ESSENTIAL OILS (STAY STRONG) FOR DAIRY CALVES 
KELLY ANN FROEHLICH 
2016 
Stay Strong (SS, Ralco Inc., Marshall, MN) is a blend of essential oils (EO) and 
prebiotic fiber technologies designed to promote immunity and stimulate appetite, 
helping to diminish health challenges and stresses experienced by newborn calves. 
Current feeding inclusion rates are unknown to achieve optimal performance in the first 8 
weeks of life. The study objectives were to determine the optimal feeding inclusion rate 
of SS when added to milk replacer (MR) to achieve optimal performance when compared 
to a yeast cell wall (YCW). One hundred Holstein calves were blocked by birth date and 
randomly assigned to 1 of 5 treatments. Treatments were: Control (C): a 24:20 MR, EO 
mixed into 24:20 MR at a rate of 1.25 g/feeding (EO-0.5), 2.5 g/feeding (EO-1.0) or 3.75 
g/feeding (EO-1.5), or 24:20 MR with an inclusion of YCW at a rate of 2 g/calf/feeding. 
Calves were sourced from a commercial dairy farm where they were fed colostrum for 
the first 2 d and then were transported to South Dakota State University (SDSU). The 
24:20 MR was fed via bucket 2 x/d at a rate of 0.28 kg/calf/d for 14 d, increased to 0.43 
kg/calf until 35 d and were reduced to 1 x/d at 36 d to facilitate weaning at 42 d. 
Decoquinate was added to MR at 37.8 g/ton for coccidiosis control. Calves were housed 
in individual Calf-Tel hutches bedded with straw with ad libitum access to a 20% CP calf 
starter (CS) and water. It was hypothesized that calves supplemented with the medium 
dose (EO-1.0) of the commercial EO would be most optimal, and in general calves 
supplemented with commercial EO would have improved growth, health, and immunity 
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compared to calves not supplemented. All data was analyzed using PROC MIXED in 
SAS as a completely random design. Calves fed EO-0.5 demonstrated greater ADG 
(0.65, 0.71, 0.64, 0.64, and 0.63 kg/d for C, EO-0.5, EO-1.0, EO-1.5, and YCW, 
respectively) through 56 d compared to calves fed EO-1.0 and YCW, and tended to be 
greater for C and EO-1.5. Total body weight gains (36.8, 39.9, 35.5, 35.8, and 35.4) were 
greater for calves fed C and EO-1.5 compared to calves fed EO-1.0 and YCW.  Body 
length gains were greater for calves fed EO-0.5 compared to calves fed other treatments. 
Hip width gains were similar among treatments. Wither height gains were greater for 
calves fed EO-0.5 compared to calves fed the remaining treatments. Hip height gains 
were also increased for calves fed EO-0.5 compared to calves fed C, EO-1.0, and EO-1.5, 
while being similar for calves fed YCW. These results demonstrate that supplementing 
EO-0.5 (1.25 g/calf/d) in a 24:20 MR may be optimal to enhance growth rates compared 
to calves fed a 24:20 MR and a 24:20 MR containing YCW technology or other inclusion 
rates of EO. 
Keywords: Calf, essential oils, yeast cell wall
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CHAPTER 1: LITERATURE REVIEW 
INTRODUCTION 
 Animal agriculture is under increasing scrutiny as social pressures and new laws 
have prohibited and restricted the use of antibiotics in animal production. These social 
changes are severely impacting agriculture on the treatment and prevention of illnesses in 
livestock. Dairy calves in particular are feeling the impact. Raising calves is both 
expensive and labor intensive. Successful calf rearing programs are designed to grow 
fast, healthy calves that are weaned at a young age to be the most economical. This 
naturally puts a lot of stress on a newborn animal. 
 In the past, it was not uncommon to supplement milk replacer (MR) fed to calves 
with antibiotics to combat these stresses and prevent any illnesses that might naturally 
occur. There have been numerous studies demonstrating the benefits of adding antibiotics 
in MR including increased gains, feed consumption, and decreased scours, mortality, and 
protein requirements (Morrill et al., 1976).  However, antibiotic supplementation in MR 
is becoming more difficult as new FDA laws restrict the use. As an antibiotic alternative, 
many new technologies are being studied, to decrease calf morbidity and mortality, and 
include nutritional additives such as essential oils (EO) or microbial additives, such as 
yeast. Many of these technologies show promising benefits that could improve calf 
performance, health, and immunity.  
ESSENTIAL OILS 
Essential oils are a diverse group of secondary plant metabolites that contain 
naturally occurring volatile components that support smell and taste of plants 
(Calsamiglia, et al. 2007). In nature, EO play an important role in allelopathic 
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communication between plants, attracting insects for pollination and dispersal of seeds, 
helping to deter herbivores by reducing their appetite for the plant, and also may act as 
antibacterials, antivirals, antifungals, insecticides or herbicides (Miguel, 2010). They are 
defined as a product obtained from a plant or some parts through hydrodistillation, steam 
distillation, or dry distillation, without heating by a mechanical process (Miguel, 2010). 
Typically, EO are classified into two specific chemical groups, terpenoids (most 
common) and phenylpropanoids, which are derived from different metabolic precursors, 
contributing to more than 15,000 unique components (Miguel, 2010, Calsamiglia, et al. 
2007). 
 Essential oils offer unique properties that could be a huge potential benefit for 
animal agriculture. One such potential benefit that has a gained a lot of attention, is the 
antibacterial properties. There is excitement that EO could be a potential mechanism to 
improve feed efficiency, nutrient utilization, and animal health as an alternative to 
antibiotics. However, at this point there is still a need for more research to provide 
information for practical feeding recommendations. Most studies conducted have been 
conducted using in vitro settings with very limited research in vivo. Complicating matters 
more, differences in EO efficacy varies depending on what part of the plant is harvested, 
time of year, where it was grown, and chemical type (chemical structure) (Calsamiglia, et 
al. 2007).  Inconsistencies of results also arise between research trials due to differences 
involving diet, dosage rates, and animal management. As will be reported in the 
following section, this literature summarization of some the important EO properties and 
studies outlining EO potential benefit for animal agriculture.  
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Antibacterial Modes 
 Contrary to their name, EO are not true oils, but are lipids. The hydrophobic 
nature of EO contributes to its antimicrobial properties. It is through antimicrobial 
properties that allows the alteration of bacterial growth and bacterial metabolism. A 
couple modes of action have been identified, and is not likely caused by one specific 
mode, but several target areas in the bacterial cell (Benchaar et al., 2008, Dorman and 
Deans, 2000).  
Essential oils have a high affinity for the lipid components in the bacterial cell 
membranes. This affects cell membrane processes and thought to cause interruptions in 
processes, such as electron transport, ion gradients, protein translocation, 
phosphorylation, and other enzyme-dependent reactions (Dorman and Deans 2000).  
One such reaction involves conformational changes in bacterial cell membrane 
structure causing loss of membrane stability. It is hypothesized this happens when the EO 
accumulates in the lipid bilayer of the bacteria cell membrane resulting in fluidification 
and membrane expansion, causing the membrane to become leaky and decreasing the 
transmembrane ionic gradient (Griffen, et al. 1999). This loss of membrane stability 
affects a wide range of microorganisms including gram-positive (GP) and gram-negative 
(GN) bacteria however, GP bacteria are more sensitive to EO. It is thought (GN) bacteria 
are less susceptible because the outer cell wall is hydrophilic, thereby preventing 
lipophilic essential oils from penetrating this barrier (Benchaar et al., 2008, Calsamiglia 
et al., 2007). This interaction and subsequent loss of membrane stability typically does 
not result in bacterial cell death, but results in slowed bacterial growth, which causatively 
also affects the rumen fermentation profile (Griffen, et al. 1999).  
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Oregano 
 Origanum vulgare, also known as oregano, is one well known EO that is shown 
to disrupt bacterial cell membrane ion gradient, inhibiting both GP and GN bacteria 
(Helander et al., 1998, Dorman and Deans 2000). The active components of oregano are 
thymol and carvacrol, which chemically are a terpenoid with a phenolic structure. It has 
been suggested that phenolic compounds, such as thymol and carvacrol, have effective 
antimicrobial activity due to hydroxyl groups in the phenolic structure (Benchaar et al., 
2008). These active components are thought to disrupt the bacterial cell membrane in 
several different ways. One study demonstrated that the proton motive force was 
disrupted, and that the H+ and K+ ion gradients were dissipated affecting intracellular 
ATP processes (Benchaar et al., 2011). Another proposed mechanism is similar to that of 
ionophore antibiotics involving the hydroxyl group acting as a trans-membrane proton 
carrier (Benchaar et al., 2011).   
 Essential oils, such as oregano that have active components containing phenolic 
structures have been shown to be highly effective against specific microorganisms 
(Dorman and Deans 2000, Benchaar et al., 2008), and has been well documented in many 
lab based settings. One study conducted by Helander et al. (1998) reported that oregano 
inhibited GN bacteria, such as Escherichia coli, and Salmonella tryphimurium. This is 
further supported by Marino et al. (2001), who reported that oregano not only inhibited 
GN Escherichi coli and Salmonella tryphimurium, but also Proteus mirabilis, Pro. 
Vulgaris, Serratia marcescens, Yersinia enterocolitica, Pse. Fluorescens and Pse. Putida. 
Oregano was shown to have inhibitory effects against a wide range of bacteria including 
GP bacteria, such as Micrococcus sp., Sarcina flava, S. aureus, B. licheniformis, B. 
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thuringiensis and L. innocua. Furthermore, compared to other EO, oregano was the most 
effective and in high concentrations (800 ppm) caused 100% inactivation of all the tested 
bacteria (Marino et al., 2001). It has been suggested as well, that certain EO may have the 
ability to inhibit parasites, such as Cryptosoridium, coccidia, and nematodes (Benchaar, 
et al. 2007).   
Bampidis et al. (2006) conducted an in vivo study using calves that exhibited 
Escherichia coli scours. Administration of dried oregano leaves in a liquid solution, may 
be as effective in the treatment of E. coli scours, as an oral solution of neomycin sulphate. 
In this study, calves were treated with either 10 mg of neomycin sulphate per kg of calf 
weight or 10 mg of oregano per kg of calf body weight per 24 hours with results 
indicating no significant differences in overall scouring days or calf mortality (Bampidis, 
et al. 2006). These results should be interpreted with care as administration of oral plant 
components could have the possibility of controlling a wide range of microorganisms, 
that could also cause an imbalance in normal gut microorganisms. Potentially allowing 
pathogens an opportunity to become established in the gut with detrimental results 
(Dorman and Deans 2000). More research needs to be conducted to elucidate the optimal 
EO inclusion rates that are effective at controlling various pathogens without inhibiting or 
consequentially affecting other beneficial gut organisms or processes.  
High dosages of EO, such as oregano and its major constituents (carvacrol and 
thymol), has been shown to inhibit rumen microbial fermentation. In an in vitro study 
conducted by Busquet et al. (2006), high dosage (3,000 mg/L) of oregano oil resulted in 
decreased rumen total concentration of volatile fatty acids (VFA), ammonia N, and an 
increase in ruminal pH, and this was true for almost all of the EO evaluated. These results 
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indicate that EO, such as oregano oil, may be detrimental to rumen microbial 
fermentation at high dosages (3,000 mg/L), but at marginal (300 mg/L) and low dosages 
(3 mg/L) can be administered safely without inhibiting rumen fermentation (Busquet, et 
al. 2006). These results correspond well with other in vitro studies Castillejos et al. 
(2007) reported that a high dose (500 mg/L) of EO including oregano, decreased total 
VFA concentrations, ammonia N, and increased ruminal pH, and acetate to propionate 
ratios. Lower dosages (5 and 50 mg/L) had no effect on ammonia N, rumen pH, acetate 
to propionate ratios, but did increase concentration of VFA (Castillejos, et al. 2007).  
Testing the pure components of oregano, such as thymol also yields similar 
results in terms of rumen fermentation (Calsamiglia et al., 2007). It was suggested that 
ruminal deamination was inhibited when there was an accumulation of AA and a 
reduction in ammonia N concentrate in an in vitro study incubated with casein in rumen 
fluid containing thymol (1000 mg/L). Overall, there seems to be a consensus that thymol 
demonstrates similar results in vitro as oregano. At higher doses, thymol can affect 
overall nutrient digestion, decrease volatile fatty acid production, decrease ammonia N 
concentrations and that overall microbial metabolism within in the rumen is inhibited. It 
has been suggested that an optimal dose of thymol ranges approximately between 50 and 
500 mg/L (Calsamiglia et al., 2007). 
Carvacrol, the other main active component of oregano, has been suggested to 
either inhibit proteolysis or stimulate peptide lyses. An in vitro study using higher doses 
of carvacrol (300mg/L) decreases acetate-to-propionate ratios, VFA production, and 
increases pH and butyrate proportion. Lower doses (2.2 mg/L) decreased large peptide 
concentrations and increased ammonia N concentrations (Calsamiglia et al., 2007).  
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In both the pure components of oregano and oregano itself, in vitro studies 
demonstrate similar results in that high dosages can be inhibitory to ruminal 
fermentation. At moderate doses, there can be beneficial effects, however it is hard to 
quantity what that optimal dose should be. The optimal dosage maybe dependent on type 
of diet fed to the animal and has been suggested that pH can play a role. The 
antimicrobial effect of thymol has shown pH dependency, the lower the pH (6.5 versus 
5.5) the more efficacious the effect. Furthermore, the percentage of active ingredients in 
oregano (carvacrol and thymol) are dependent on specific cultivar and processing 
methods. The chemical structures of thymol and carvacrol are different and these 
variations in chemical structures can affect results (Calsamiglia et al., 2007). 
Essential oils and calves 
 Very limited EO research exists in vitro and even less in vivo results are available 
in dairy calves. Published results among projects are variable but shows many promising 
benefits, however more research needs to be done on optimal dosage and routes of EO 
supplementation.  Hill et al. (2007) reported improved average daily gains (ADG), calf 
starter intake (CS) and efficiency in pre-weaned calves fed a commercial blend of 
essential oils. There were two studies conducted. Study one fed calves either an all MR or 
a MR with 45% of the crude protein from soy protein with or without the mix of EO. In 
study two, calves were fed with or without EO in the CS. The MR was formulated to be a 
20:20, and the CS was formulated to be 18% CP. All inclusion of EO was fed a 0.05% of 
either the CS or MR or both. Calves were less than seven days old when enrolled in the 
trial and were weaned at 42 days of age. At the conclusion of both studies, calves 
supplemented with the commercial blend of EO had improved body weight gains, CS, 
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and feed efficiency (FE) compared to calves that were not fed EO. It was also noted that 
inclusion of the EO in both the CS and MR had additive effects on calf performance in 
improved body weight gains and feed efficiency (Hill et al., 2007).  
 Santos et al. (2015), reported no increase in calf performance or health when 
calves were supplemented with a commercial EO blend. In this study, neonatal calves 
were fed a 20:15 MR and a 26% crude protein CS and were assigned to one of three 
treatments: 1) Control with no added EO to MR or CS; 2) MR supplemented with 400 
mg/kg of EO; and 3) EO supplemented at 200 mg/kg in both MR and CS. The authors 
reported no treatment differences in feed intake, body weight, structural gains, ADG, 
blood metabolites (plasma β-hydroxybutyrate and glucose), fecal scores, and counts of 
intestinal microorganisms (enteboracteria and lactic acid bacteria). Rumen fluid samples 
collected from the calves demonstrated no difference in ruminal pH, VFA, acetate to 
propionate ratio, or counts of protozoa, cellulolytic and amylolytic bacteria. However, 
ammonia-N concentrations were significantly higher in calves supplemented with EO in 
MR and CS. It was concluded that addition of EO in the MR, CS, or both did not hinder, 
but also did not improve the health or performance of dairy calves (Santos et al., 2015).  
 In a post-weaned study, Vakili et al. (2013) supplemented Holstein calves fed a 
high concentrate diet with either thyme or cinnamon EO. This study utilized three 
treatments: 1) control with no EO supplemented to the diet; 2) control diet with 5 grams a 
day per calf of thyme EO added; and 3) control diet with 5 grams a day per calf of 
cinnamon EO added. Diets fed were a total mix ration (TMR) composed of 15% alfalfa 
hay and 85% concentrate and formulated to meet NRC (1996) nutrient requirements. 
Similar to the study conducted by Santos et al. (2015) in pre-weaned calves Vakili et al. 
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(2013) reported no effect on calf performance in ADG, FE, DMI, blood metabolites 
(glucose, urea N, triglyceride, total cholesterol, β-hydroxybutyrate, alanine 
aminotransferase, aspartate aminotransferase). Rumen fermentation was also similar 
among treatments for ruminal pH, ammonia nitrogen, and total VFA. There was however, 
a decrease in molar proportions of calves supplemented with EO compared to control 
calves in acetate to propionate ratios, and acetate levels. Molar proportions of propionate 
were increased for calves supplemented with EO compared to control, Butyrate 
proportions were also significantly increased for calves fed the cinnamon EO over the 
control calves (Vakili et al., 2013).    
PREBIOTICS 
 Prebiotics are non-digestible food additive that promote the growth and activity of 
specific gut microbes that beneficially affect the host (Samanta et al., 2012 and Uyeno et 
al., 2015). Specifically, prebiotics are carbohydrate biomolecules in the form of fructans. 
There are a variety of biomolecules that can be considered as a prebiotic, which can be of 
plant origin, or obtained from microbial additives such as yeast. These molecules can be 
further classified into a variety of subcategories, such as oligosaccharide, polysaccharide, 
or trisaccharide (Samanta et al., 2012). Some examples of oligosaccharides used in in the 
livestock industry are Mannan-oligosaccharide (MOS), or Fructooligosaccharides (FOS), 
galactosyl-lactose is a trisaccharide, and a well-known polysaccharide is inulin.  
 In ruminants, rumen microbes can ferment prebiotics and utilize it as a source of 
energy. The non-digestibility of prebiotics ensures that the microbes receive it as an 
energy source and is used directly by the host. This subsequently can cause an alteration 
in the microbial population activity and composition which can result in other effects, 
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such as drop in pH and increased gas production (Papatsiros et al., 2013). Furthermore, 
these prebiotics when fed have demonstrated increases in N retention, beneficial 
microflora, weight gain in calves, decreased rumen ammonia nitrogen, and better fecal 
consistency in calves (Samanta et al., 2012). It has been suggested, that prebiotics can be 
advantageous to ruminants when exposed to a variety of stresses, such as transportation, 
weaning, etc. that can result in a variety of adverse health events. Prebiotics promote the 
growth and activity of healthy gut microflora excluding pathogens that can reduce the 
adverse health events caused by stress, such as diarrhea, depression of growth and feed 
intake (Samanta et al., 2012 and Uyeno et al., 2015). It has also been shown that 
prebiotics can reduce the colonization of gut pathogens such as Salmonella and E. coli 
(Papatsiros et al., 2013), as well as, increase concentrations of immunoglobulins 
(Heinrichs et al., 2009). These characteristics specifically can have beneficial results in 
neonates in which the gut microflora is adapting and developing under a variety of 
stresses.  
Feeding oligosaccharides to calves has shown similar results as supplementing 
antibiotics in milk replacer (Quigley et al., 1997 and Donovan et al., 2002). 
Supplementation of galactosyl-lactose increased body weight gain, feed efficiency and 
decreased severity of scours when supplemented to calf MR, contributing to increased 
intestinal health (Quigley et al., 1997). In a commercial prebiotic mix fed to calves 
tended to increase beneficial bacteria, such as Lactobacilli and increased fecal IgA, which 
suggested an increased intestinal health (Heinrichs et al., 2009). Similarly, MOS, and 
FOS have shown promising benefits in calf health and performance (Uyeno et al., 2015).   
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Modes of Action  
 Prebiotics promotes its benefits through a variety of mechanisms. Consumption 
of prebiotics results in the production of short chain fatty acids (propionate, acetate, 
butyrate) and lactic acid which decreases luminal pH. Decreased luminal pH is also 
thought to play an important role in enhancing mineral absorption, as some minerals, 
such as calcium has a higher solubility in lower pH and increases the gradient across the 
epithelium. It is hypothesized that the feeding of prebiotics interacts with the intestinal 
tight junctions in the epithelium increasing the permeability for mineral absorption. 
Calcium, magnesium, iron, and zinc have all demonstrated increased absorption with the 
feeding of prebiotics (Samanta et al., 2012).     
Production of butyric acid promotes stimulation of goblet cells and subsequent 
increased mucous production in the intestines, which plays an important role in immune 
defense. Butyric along with lactic acid production plays an important role in gut 
epithelium development, increasing length and width of crypts and subsequent nutrient 
absorption (Samanta et al., 2012).   
 Consumption of prebiotics has also been shown to increase beneficial bacteria in 
the intestine such as Bidobacteria and Lactobacilli. The production of these bacteria are 
beneficial due to their ability to produce short chain fatty acids, reduce gut pH, ferment 
non-digestible carbohydrates, and stimulate immunoglobulin production (Samanta et al., 
2012). These beneficial bacteria exclude gut pathogens through competitive exclusion by 
suppressing growth, reducing toxic fermentation products. This is accomplished by 
preventing the adhesions of pathogens to mucosa by competing with the sugar receptors 
(Samanta et al., 2012 and Papatsiros et al., 2013). 
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Mannan-oligosaccharide (MOS) 
 Mannan-oligosaccharide is a mannose sugar that is derived from the cell wall 
fragments of yeast, such as Saccharmyces cerevisiae. It is known for its ability to adsorb 
pathogens with type-1 mannose-specific fimbriae that are found in many GN bacteria, 
such as Escherichia coli and Salmonella. This increases competition for binding sites on 
the intestinal epithelium, decreasing the pathogens ability to colonize the gastrointestinal 
tract (Heinrichs et al., 2003 and Brady et al., 2015). This allows MOS with the ability to 
help improve immunity, performance, and health of dairy calves.  
 There has been varying results published in literature on calves supplemented 
with MOS. Heinrichs et al. (2003), found that when Holstein calves were supplemented 
with MOS they performed similarly as calves supplemented with antibiotics. In this 
study, calves were randomly assigned to one of three treatments: 1) control 20:20 all MR; 
20:20 all MR with 400g/440 kg of neomycin + 200 g/440 kg of oxytetracycline; and 3) 
20:20 all MR with 4 g calf/ d of Bio-Mos supplemented. It was found that calves 
supplemented with antibiotics and MOS had a greater probability of having normal feces 
throughout the study meaning less scours overall compared to control calves. There was 
no difference in ADG or FE among the three treatments. However, calves supplemented 
with MOS had significantly higher grain intakes during week six (when calves were 
weaned) than that of calves supplemented with antibiotics. Greater feed intake did not 
affect growth performance such as body weights and body parameters (hip width, wither 
height, heart girth, hip height) were similar among treatments. The authors reported no 
significant differences in metabolic problems between calves, blood urea N and total 
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blood protein between treatments. It was concluded that MOS could be as effective as an 
antibiotic alternative in calf MR (Heinrichs et al., 2003).  
 Similarly, Terre et al. (2007), found that supplementing a MOS product 
stimulated an increase in CS intake after weaning, as did Heinrichs et al (2003), but did 
not improve growth rates. In this study, Holstein calves were enrolled in an enhanced-
growth feeding program in a group pen. Calves were assigned to one of two pens; pen 
one calves were fed MR supplemented with 4 g/d of Bio-Mos, pen two was control 
calves just fed MR with no supplementation. Calf performance throughout the trial was 
similar between treatments. Body weight, and ADG, and gain: feed was not significantly 
different between treatments (P > 0.05). Dry matter intake of MR and CS were similar 
with the exception of MOS supplemented calves having higher CS intake compared to 
control calves right after weaning. The incident of loose feces or scours between 
treatments were similar as well as total fecal counts of Escherichia coli and Clostridium 
perfringens. Numerically, the probability of observing presence of Cryptosporidium in a 
fecal smear was lower for calves supplemented with MOS compared to control calves in 
the first two weeks of the study. However, in week three the control calves had 
numerically lower presence of Cryptosporidium than calves supplemented with MOS. 
Lastly, there was no difference in serum haptoglobin concentrations between treatments. 
The authors concluded that supplementing calves with MOS did increase CS intake after 
weaning, but did not affect the growth performance, nor reduced fecal bacterial counts in 
calves (Terre et al., 2007).  
 Unlike Heinrich et al (2003) and Terre et al. (2007), Ghosh and Mehla (2012) 
reported that supplementing cross-bred dairy calves with 4 g/d of Bio-Mos compared to 
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control calves increased body weight gain. Feed intake overall was increased throughout 
the study, however the results were not separated by pre- and post-weaning stages so it is 
difficult to ascertain if similar patterns were observed as reported by Heinrich et al (2003) 
and Terre et al. (2007) were intake was increased just after weaning. Fecal scores for 
calves supplemented with MOS was significantly lower compared to control calves and 
unlike Terre et al. (2007), there was a significant decrease in fecal coliform counts 
(Ghosh and Mehla, 2012).  
 It has also been hypothesized that feeding of MOS to dry cows pre-calving or 
supplementing calves with MOS in colostrum could improve immunity. Franklin et al. 
(2005) reported that supplementation of periparturient dairy cows with MOS resulted in a 
tendency for calves to have increased serum protein concentrations (passive transfer) 
from birth to 24 hours of age. Supplementing the ration with MOS enhanced the cow’s 
immune response to vaccination such as rotavirus, which resulted in the calves receiving 
better antibodies against rotavirus. It was proposed that MOS supplementation to 
periparturient cows could enhance immunity transfer to calves leading to better calf 
immunity when born, which could result in decrease treatment costs (Franklin et al., 
2005). Increased serum protein concentrations were not observed when calves were 
supplemented with 30 g of MOS in the colostrum. Colostrum supplementation with MOS 
actually resulted in negative effects. Brady et al. (2015) recommended not to supplement 
MOS in calf colostrum. In that study, MOS supplementation in fresh maternal colostrum 
led to lower apparent efficiency of IgG absorption and reduced serum IgG concentrations 
compared to control calves (Brady et al., 2015). These results are similar to Robichaud et 
al. (2014), who reported that MOS supplementation to colostrum calf replacer resulted in 
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similar apparent efficiency of absorption of IgG and serum IgG concentrations compared 
to control. It was also reported that there were no effects on incidences of diarrhea, 
pneumonia, survival, or ADG in calves supplemented with MOS in colostrum replacer 
between birth and weaning (Robichaud et al., 2014).   
Fructo-oligosaccharides (FOS) 
 Fructo-oligosaccharide is a soluble fiber that is composed of several β-(1,2) or β-
(1,6) linked fructose residues. It is obtained from the partial hydrolysis of inulin, a 
carbohydrate energy source for plants most often sourced from chicory root (Franck, 
2006). Fructo-oligosaccharide is known to stimulate the production of beneficial bacteria 
in the gut, including Bifidocteria and Lactobacilus, which can ferment FOS to short chain 
fatty acids (Quigley et al., 2002, Grand et al., 2013, and Jenkins et al., 1999). Increased 
production of short chain fatty acids is used as a source of energy, can enhance mucosal 
structure, and prevent the colonization of pathogens, such as Clostridium difficile (Grand 
et al., 2013 and Donovan et al., 2002).   
 In rat and human studies, FOS or oligofructose, has shown clear benefits in 
mineral absorption and bone mineralization. Supplementation of FOS demonstrated that 
calcium and magnesium absorption is enhanced (Franck et al., 2006). It has also been 
shown that FOS increases calcium balance, true and apparent intestinal absorption and 
mineral density in growing rats (Morohashi, 2002).  
 In calves, studies evaluating FOS supplementation reported that calf performance 
can be enhanced as a result of the modification of microbial fermentation activity, 
possibly as an antibiotic replacement, and a useful tool in times of stress (Grand et al., 
2013, Quigley et al., 2002, and Donovan et al., 2002). Grand et al. (2013), studied the 
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effects of different FOS dosages on the growth performance, carcass characteristics and 
fecal concentrations of short chain fatty acids on Holstein cross veal calves. Calves were 
fed a MR containing 5% soluble wheat proteins and supplemented with either 0, 3, or 6 
g/d of FOS. Body weight, cold carcass weight, DMI, ADG, and feed conversions were 
similar between treatments. Numerically, calves supplemented with FOS had a reduction 
in feed conversion and increased carcass weight, and ADG. There was also an 
observation of an overall increased production of short chain fatty acids with an increased 
percentage of butyrate and a decrease in acetate production in calves supplemented with 
FOS compared to control, however not statistically significant. It concluded that 
supplementation of FOS in MR allowed enhanced growth parameters (Grand et al., 
2013).  
Grand et al. (2013) reported results similar to Kaufhold et al. (2000) who fed veal 
calves supplemented with or without FOS. Kaufhold et al. (2000), reported that calves 
supplemented with 10 g/d of FOS tended to have greater weight gains compared to 
control calves. Feed intakes among the two treatments were similar. Instead of studying 
carcass and short chain fatty acids in feces, Kaufhold et al. (2000) was interested in 
metabolic and endocrine functions of calves supplemented with FOS. It was reported that 
FOS supplementation decreased post-prandial glucose and increased insulin 
concentrations in very small amounts when calves were given lactose. It was concluded 
that FOS had similar effects on the metabolic and endocrine traits as humans with 
diabetes mellitus and that FOS may aid in coping with insufficient control of glucose 
metabolism (Kaufhold et al., 2000).  
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 Quigley et al. (2002) studied the effects of feeding spray-dried animal plasma 
with or without the addition of FOS on the growth and health of calves. This study was 
conducted into two separate experiments in which Holstein calves were used. Calves 
were fed MR in study one with 0 to 20% of the crude protein being spray-dried animal 
plasma and experiment two was with 0 to 16% of the crude protein containing spray-
dried animal plasma. Both studies had treatments containing 30 or 60 g of additive that 
had FOS added that contained either bovine serum or whey protein. In both studies, 
calves fed milk with FOS had fewer scour days, and improved fecal scours compared to 
calves fed control. One experiment reported increased body weight gain and subsequently 
feed efficiency when feeding FOS compared to control fed calves (Quigley et al., 2002).  
IMMUNITY 
Immunity plays an important role in calf health and is often an overlooked area of 
research. Immunity is the normal function of the immune system that helps to keep an 
individual healthy by maintaining homeostasis by recognizing and attacking foreign 
substances that disrupts balance. The immune system can be classified into two distinct 
types: innate and acquired/adaptive immune responses. Innate immune system is referred 
to as the first line of defense and is non-specific in nature. In neonates, the innate immune 
system is the most important, because it is what the calf is born with. Development of the 
calf is required to develop an acquired/adaptive immune system.  Innate immune system 
uses mechanisms, such as external defenses, which include the use of physical barriers, 
like skin, mucous, etc. It can use internal defenses, such as phagocytic cells such as 
macrophages. Both external and internal defenses are used to keep and clear foreign 
substances from the body. The innate immune cells can also release signaling proteins, 
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such as cytokines, that help connect to the adaptive immune response (Mak et al., 2014 
and Lippolis 2007).  
The adaptive immune system is the second line of defense and is considered 
specific in nature because it is designed to recognize and remember specific pathogens. 
Adaptive immune response is triggered when signals are received from the innate 
immune system (cytokines) when the system is unable to remove or overcome a threat. 
Adaptive immunity is divided into both passive and active immunity. Active immunity is 
developed upon contact with an antigen, pathogen, or vaccination which can be further 
divided into humoral and cell-mediated immunity. Humoral immunity is composed of B-
cells that are produced and mature from the bone marrow, that become antibody-
producing or memory cells. The cell-mediated immunity is composed of T-cells that 
mature in the thymus to give rise to T-helper or T-cytotoxic cells. B-cells are specialized 
to recognize whole antigens, whereas, T-cells recognize fragments of antigens presented 
on the major histocompatibility complex molecules which are used to enhance immune 
responses. Overall, active immunity uses humoral and cell-mediated approaches to 
mature B-cells into making their own antibodies. (Mak et al., 2014 and Lippolis 2007). 
Passive immunity is recognized as the transfer of antibodies to a non-immune 
individual, such as antibodies received by a neonate from its mother. Compared to active 
immunity, this is a relatively fast immunity development. Passive immunity is vitally 
important for neonatal calves as they are born agammaglobulinemic (no antibodies). 
Neonatal calves are unique in that they receive no maternal antibodies 
(immunoglobulins) via placental transfer. Immunoglobulins are taken up mostly across 
the gut epithelium by receiving colostrum, making it imperative that quality colostrum is 
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received when they are born (Pastoret et al., 1998). Passive immunity is an evolutionary 
response that has developed as antibodies, such as immunoglobulin G (IgG), may take as 
long as 6-12 months to develop adequate amounts in serum and secretory Igs to be 
produced by the newborn (Mak et al., 2014).  
Immunoglobulins (Ig) 
 Antibodies or immunoglobulins are glycoproteins members of the 
immunoglobulin super family. Their basic structure is composed of two light chains and 
two heavy chains, which come together to form a Y shaped molecule. These molecules 
have two Fab sections that retains antibodies antigen-binding ability and one Fc region 
that is considered the tail of the antibody. This Fc region does not bind to antigens, but 
instead recognizes and binds to Fc receptors on innate cells, and controls antibody 
effector functions. There are four antibody effector functions which include 
neutralization, classical complement activation, oponization, and antibody-dependent 
cell-mediated cytotoxicity (ADCC) (Mak et al., 2014). When an infection or vaccination 
occurs there is a humoral immunity response in which immunoglobulins are secreted and 
the foreign entity or pathogen is eliminated or neutralized through the effector functions. 
There are five different immunoglobulin isotypes- IgG, IgA, IgE, IgD and IgM. Each 
type has different biological functions and physical properties; typically IgG, IgA, and 
IgM are found in serum and IgD and IgE are only found in serum in low concentrations 
(Cervenak and Kacskovics, 2009).  
Immunoglobulin G (IgG) 
Immunoglobulin G is the most common immunoglobulin isotype found in tissue 
and blood with a long half-life (Cervenak and Kacskovics, 2009). There are three 
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recognized subclasses recognized in bovine; IgG1, IgG2, and IgG3 (Pastoret et al., 1998). 
The IgG class uses a mix of antibody effector functions including opsonization, ADCC, 
and classical complement activation to eliminate pathogens. Opsonization and ADCC are 
exerted by the FcγR- bearing cells, such as phagocytes and lytic cells, that has a high 
affinity to IgG1 and IgG3 subclasses (Mak et al., 2014).  
Calves are born agammaglobulinemic and must receive maternal antibodies 
through colostrum. Bovine colostrum is specifically high in IgG (Pastoret et al., 1998), 
and has a 90% absorption rate (Roy, 1979). Specifically, colostrum is composed mainly 
of IgG1 subclass, which binds to FcRn (neonatal Fc receptor) antibodies with a high 
affinity. This FcRn receptor is important in transporting maternal immunity and protects 
IgG from fast degradation until the calf is able to develop their own antibodies (Cervenak 
and Kacskovics, 2009).  
Ingestion of colostrum is time dependent and it is important for a calf to receive 
colostrum before gut “closure” and before establishment of gut microflora, otherwise 
bacteria can be absorbed the same way as maternal IgG (Roy, 1979). It is critical for 
calves to receive colostrum for adequate IgG absorption within the first 24 hours. Calves 
are 74 times more likely to die in the first 3 weeks if they do not receive colostrum 
(Hulbert and Moisa, 2015).  Furthermore, calves that do not receive adequate amounts of 
colostrum with low IgG absorption are said to have a failure of passive transfer. 
Successful passive transfer is defined as having a serum IgG reading of above 10 mg/mL 
by 48 hours of age. Generally, higher serum IgG levels are associated with healthier 
calves that have lower morbidity and mortality rates (Barrington et al., 2001).  
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Immunoglobulin A (IgA) 
Immunoglobulin A is often considered the first line of defense when it comes to 
immunoglobulins because it binds to pathogens at the mucosal surfaces, which are 
common sites of pathogen attacks (Mak et al., 2014). It is found in a secretory form 
referred to as secretory IgA (SIgA), such as tears, saliva, milk, and mucus, and is 
produced in the gastrointestinal, urogenital, and respiratory tracts. Immunoglobulin A 
uses neutralization by cross-linking microorganism and macromolecules to prevent 
pathogens from attaching to the surface of epithelial cells at mucosal surfaces (Corthesy, 
2013 and Mak et al., 2014). Low production of IgA is linked to a variety of recurring 
gastrointestinal, respiratory infections and even allergies/asthmas in humans (Corthesy, 
2013).   
The serum concentration of IgA is found to be low and is lower in bovine 
colostrum then IgG (Pastoret et al., 1998), but never less still important. When a calf 
receives colostrum there is a high concentration of serum IgA but disappears quickly into 
the intestinal lumen. High concentration of immunoglobulins (300 to 400 g Ig in first 48 
hours) from colostrum regardless of isotype are associated with reduced calf mortality 
and morbidity and is vitally important (Roy et al., 1979). Calves that receive no colostral 
Igs will remain basically agammaglobulinemic until immune system develops leaving the 
calf susceptible to infections and even death (Butler, 1969). 
 
CONCLUSION 
 Milk replacer additives such as EO or prebiotics show many promising benefits to 
increase calf health and performance with the out use of antibiotics. However, more 
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research needs to be conducted to elucidate the optimal dosages, and the most efficacious 
to enhance calf growth, performance, and health. Furthermore, it is important to 
understand calf immunity and ways to improve immunity; either through feed additives 
or changing the management of calves to reduce stresses. This literature review was to 
illuminate the current research conducted to date leading well into the study presented in 
the next chapter evaluating a commercial blend of EO and prebiotics, mainly oregano, 
and how performance compares to prebiotics or calves not supplemented with either 
additive.  
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CHAPTER 2: EVALUATION OF STAY STRONG FOR DAIRY CALVES 
INTRODUCTION 
 Neonatal calves often experience numerous stresses caused by being exposed to 
pathogens eliciting various enteric and respiratory problems resulting in pre-weaning 
deaths. The United States has a 7.8% mortality rate in pre-weaned heifer calves. Of these 
mortality rates, 56.5% is attributed to scours and digestive problems and another 46.7% is 
attributed to respiratory problems (USDA-NAHMS, 2007). Supplementing antibiotics in 
MR has many benefits including reduction in mortality rates, scours and increased feed 
consumption and gains (Morrill et al., 1977). However, increased FDA regulation and 
public scrutiny makes the supplementation of antibiotics in MR quite difficult. It is 
estimated that the treatment of respiratory and enteric problems in calves exceeds $250 
million annually (Simmons and Bywater, 1991). This is of huge economic significance to 
the industry, resulting in investigations for identifying alternatives to antibiotics.  
One such alternative is the use of essential oils (EO). Essential oils are a diverse 
group of secondary plant metabolites and contain naturally occurring volatile components 
that support the smell and taste of plants (Calsamiglia et al., 2007). In nature, EO play a 
role in attracting insects, and allelopathic communication in plants. Additionally, EO may 
also act as antibacterials, antivirals, antifungals, insecticides, and herbicides (Miguel, 
2010). Antibacterial is one of the most noted contributing feature of EO in animal 
agriculture. It is this ability that has the potential to alter bacterial growth, by causing 
conformational changes to membrane structures affecting cell membrane processes of 
bacteria (Benchaar et al., 2007, Calsamiglia et al., 2007).  
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Typically, EO have more of an effect on GP bacteria than GN bacteria due to the 
cell membrane being less impermeable (Benchaar et al., 2007). However, certain EO 
such as oregano have been shown to inhibit growth of several GN bacteria, including E. 
coli (Marion et al., 2001). Bampidis et al. (2006), found that administration of an oral 
oregano solution to calves with E. coli scours may be as effective as neomycin. Further 
studies supplementing pre-weaned calves with EO have found increases in CS intake, 
feed efficiencies, and body gains (Hill et al., 2007). As well as increase proportion of 
beneficial microorganisms in the intestinal flora (Santos et. Al., 2015). As a result EO 
show promising benefits as a potential feed additive to help reduce neonatal stresses, 
while improving performance without the use of antibiotics. Thus, the objective of this 
study was to determine optimal inclusion rate of a commercial EO mix to promote calf 
growth, and health, when added to the MR of pre-weaned dairy calves compared to 
calves fed a control or yeast cell wall (YCW) product. It was hypothesized that calves 
supplemented with the medium dose (EO-1.0) of the commercial EO would be most 
optimal, and in general calves supplemented with commercial EO would have improved 
growth, health, and immunity compared to calves not supplemented. 
MATERIALS AND METHODS 
Calf Feeding and Management 
This research project was conducted at the South Dakota State University (SDSU) 
Animal Research Wing (ARW, Brookings, SD) from September 7 to December 8, 2015, 
all procedures were approved by SDSU Institutional Animal Care and Use Committee 
before the start of the study. One hundred Holstein calves were sourced from a 
commercial dairy farm and were housed in Calf-Tel hutches bedded with straw. Calves 
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were blocked by birth date and randomly assigned to 1 of 5 treatments.  Treatments were: 
Control (C): a 24:20 MR, EO mixed into 24:20 MR at a rate of 1.25 g/feeding (EO-0.5), 
2.5 g/feeding (EO-1.0) or 3.75 g/feeding (EO-1.5), or 24:20 MR with an inclusion of 
YCW at a rate of 2 g/calf/feeding. Essential oil was Stay Strong for dairy calves 
manufactured by Ralco (Marshall, MN) and the YCW technology (Bio-Mos) was 
manufactured by Alltech (Nicholasville, KY).  
Prior to enrollment in the study, calves were tested for successful passive transfer 
of colostrum, and bovine viral diarrhea (BVD). Successful passive transfer was 
determined by serum samples that were collect via jugular puncture and were read for 
total protein (TP) using a Brix refractometer. Calves with total protein greater than 5.5 
g/dl were considered successful. Ear notch samples were submitted to South Dakota 
Animal Disease Research and Diagnostic Laboratory (SDSU-ADRDL) for BVD testing. 
Upon arrival, calves were castrated using an elastic ring (Animal Health International, 
Greenly, CO) and vaccinated with Inforce 3 via intranasal (Zoetis; Florham Park, NJ).  
 Calves were fed colostrum before their arrival at SDSU for the first two d of life. 
A 24:20 MR was fed at a rate of 0.28 kg/calf at each feeding (0630 and 1730 h) daily for 
14 d via bucket, and then increased to a feeding rate of 0.43 kg/calf at 2x/d until 35 d. 
Feedings were reduced to 1x/d at 36 d to facilitate weaning at 42 d. Decoquinate was 
added to MR at 37.8 g/ton for coccidiosis control. A 20% CP pelleted calf starter (CS) 
and water was offered ad libitum throughout the study. All MR and CS were sourced 
from Hubbard Feeds Inc. (Mankato, MN). Intakes and refusals of CS were recorded daily 
in the morning, and any MR refusal were also recorded. Both CS and MR samples were 
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collected every two weeks and stored frozen (-20ºC) before being composited by month 
and sent to Analab (Fulton, IL) for analysis.  
Ovalbumin Vaccination  
 Calves were subjected to an ovalbumin (OVA) challenge, and were vaccinated in 
the beginning of week three (21 d) and then given a booster on week six (42 d). Calves 
were given 4 mL subcutaneously of an OVA solution in four, 1 mL injections to the side 
of the neck to minimize abscesses. The OVA solution contained 4 mg of crystallized 
OVA (Sigma Chemical, St. Louis, MO) suspended in a phosphate buffered saline (PBS). 
The concentration of the OVA-PBS solution was 2 mg of OVA/ml of PBS. The OVA-
PBS solution was filtered sterilize through a 0.45 micron filter, and was then diluted with 
1:1 (ml:ml) Freund’s incomplete adjuvant (ThermoFisher Scientific, Waltham, MA). The 
OVA-PBS-Freunds solution was emulsified using a 22 gauge micro-emulsifying needle 
and glass mixing syringes for several minutes. The OVA vaccine was transferred to 
plastic 5 mL syringes with 18 gauge needles for administration to calves. The vaccine 
was made weekly and stored in refrigerator for up to four days before administration.  
Nasal Secretion Collection and Analysis  
 Nasal secretion samples were collected from calves twice throughout the study. 
Secretion samples were collected when the calves arrived (0 d) before vaccination of 
Inforce 3 via intranasal (Zoetis; Florham Park, NJ), and again on week three (21 d). A 50 
x 55 mm foam plug (VWR, Radnor, PA) was cut into quarters and one quarter was 
inserted into the nasal cavity of the calf and was allowed to sit for 5 to 7 minutes or until 
the foam was saturated. The foam was then pulled out and inserted into a 10 mL plastic 
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syringe that was used to squeeze the nasal secretions out into a 1 mL microcentrifuge 
tube that was then stored frozen (-20ºC) until analysis. 
    Nasal secretions were analyzed for specific IgA titers to Inforce 3 against 
bovine respiratory syncytial virus (BRSV) using an enzyme-linked immunosorbent assay 
(ELISA) modified from Woolums et al. (2013). Samples were prepared using a 96-round 
well plate (Immulon 1B, VWR, Radnor, PA). Every other column of the plate was coated 
by pipetting 100 µL/well of a 1:10 dilution of UV inactivated BHV-1 Cooper strain. 
Stock solution of BHV-1 Cooper strain had a titer of 1 X 107 TCID 50/ml and was 
inactivated by placing in a hood with UV for 20 minutes which was stored at -80ºC until 
ready to use for coating. Prior to coating the UV inactivated BHV-1 Cooper strain was 
diluted 1:10 with a coating buffer which was distilled water containing 0.9% sodium 
carbonate (Sigma Chemical, St. Louis, MO) solution adjusted to a pH of 9.7. The non-
coated (no BHV-1 Cooper strain) columns served as a control to account for non-specific 
binding. All stock solutions were made fresh the day samples were analyzed. Plates were 
allowed to incubated at 4ºC for at least 12 h (overnight) before analysis, to allow 
adherence of antigen to each coated well. Following overnight incubation plates were 
emptied and washed once with phosphate buffered saline tween (washing buffer) and 200 
µL of blocking buffer solution was added to each well and allowed to incubate for 1h at 
room temperature (~22ºC). Phosphate buffered saline tween (PBST) was prepared as 
PBS with 0.05% of polyoxeyethylene sorbitan monolaurate (Tween 20, Sigma Chemical, 
St. Louis, MO). The blocking solution was prepared with phosphate buffer solution 
(PBS) that contained 0.5% bovine serum albumin (BSA, Sigma Chemical, St. Louis, 
MO). Following incubation of the blocking buffer, plates were emptied and washed 3 
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times with PBST and blotted dry. Nasal secretion samples were thawed and diluted in a 
two-fold serial dilatation with PBST that contained 0.01% bovine serum albumin (BSA, 
Sigma Chemical, St. Louis, MO). Dilution of nasal secretion samples from initial 
concentration was 1/4 for both week 0 (d 0) and week 3 (21 d). One hundred µL of the 
diluted samples were added to the wells in duplicate and incubated for 1 h at room 
temperature (~22ºC). Following incubation plates were emptied and washed 4 times with 
PBST wash buffer and blotted dry. A second antibody, rabbit anti-bovine IgA (Bethyl 
Laboratories Inc., Montgomery, TX) was diluted to a concentration of 1:2500 with PBST 
containing 0.01% BSA and 100 µL was pipetted to each well and incubated for 1 h at 
room temperature (~22ºC). Following incubation plates were emptied and washed 4 
times with PBST wash buffer and blotted dry. A tetramethylbenzidine substrate solution 
(TMB, ThermoFisher Scientific, Waltham, MA) was added at 100 µL per well and 
incubated in the dark at room temperature (~22ºC) for 20 minutes for color development. 
The reaction was stopped by adding 100 µL of a TMB stop solution to each well. Plates 
were then read at 405 nm optical wavelength using a 96-well plate reader (Biotek, 
ELx808, Winooski, VT).  
Body, Fecal and Health Measurements 
Body weights were taken weekly using a digital scale (Digi-Star, Fort Atkinson, 
WI) after morning feeding. Body measurements including wither height (WH), hip 
height (HH), hip width (HW), heart girth (HG) and body length (BL) were taken bi-
weekly at the time body weights were taken.   
Fecal samples were collected three times for each calf throughout the trial and 
were taken when they first arrived (0 d) and then the beginning of week two (8 d) and 
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week five (35 d). Samples were taken fresh to Rural Technologies Inc. (Brookings, SD) 
for analysis of Escherichia coli, Salmonella, Clostridium, and Cryptosporidium. Samples 
were analyzed using a streak plate and given semi quantitative descriptions based on 
growth of the bacteria into different quadrants of the plate. Escherichia coli descriptions 
were established as 1) none detected, 2) Rare amount, 1 phenotype, 3) rare amount, 2 
phenotypes, 4) small amount, 1 phenotype, 5) small amount, 2 phenotypes, 6) moderate 
amount, 1 phenotype, 7) moderate amount, 2 phenotypes, 8) moderate amount, 3 
phenotypes, 9) large amount, 1 phenotype, 10) large amount, 2 phenotypes, 11) large 
amount, 3 phenotypes. Salmonella, Clostridium, and Cryptosporidium descriptions: 1) 
none detected, 2) rare amount present, 3) small amount present, 4) few present, 5) 
moderate amount present, 6) large amount present, 7) many present.    
Health scores included ear, eye, nasal, and fecal scores and were recorded daily 
before evening feeding. Health scores were according to the University of Wisconsin calf 
health scoring chart (McGuirk, 2013), and were based on a 0-3 scale. Fecal scores were 
established as 0) normal, 1) semi-formed, pasty, 2) loose, but stays on top of bedding, 3) 
watery, sifts through bedding. Ear scores: 0) normal, 1) ear flick or head shake, 2) slight 
unilateral droop, 3) head tilt or bilateral droop. Eye scores: 0) normal, 1) small amount of 
ocular discharge, 2) moderate amount of bilateral discharge, 3) heavy ocular discharge. 
Nasal scores: 0) normal serous discharge, 1) small amount of unilateral cloudy discharge, 
2) bilateral, cloudy or excessive mucus discharge, 3) copious bilateral mucopurulent 
discharge. All health incidents, and treatments were recorded for the length of the study.  
Blood Sampling and Analysis 
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Blood samples were collected from the jugular vein on all calves weekly after 
morning feeding. Blood samples were collected using a 10 ml Vacutainer serum 
separation tube with a 18 gauge needle (Animal Health International, Greenly, CO). 
Samples were allowed to clot, and serum was harvested by centrifugation at 2,000 x g for 
20 min and stored frozen in 5 ml polystyrene tubes for later analysis. 
VFA- Serum samples from week 5 were analyzed for VFA concentrations using a 
GC (model 6850, Agilent, Santa Clara, CA). Samples were prepared according to the 
procedures of Oba and Allen (2003) and 1 µL of sample was injected at a split ratio of 
2:1 at the injection port (280ºC). Volatile fatty acids were separated on a capillary column 
(30 m x 0.32 mm x DB 0.25; Agilent, Santa Clara, CA) with a flow of 45 mL/min of He 
using 2-ethylbutyrate as an internal standard. Initial oven temperature was 90ºC for 5 min 
and then was increased by 10ºC/min to 150ºC, where it was held for 5 min. The oven was 
brought up to 170ºC for purging at the end of the run. The flame ionization detector was 
maintained at 300ºC.  
ELISA Ovalbumin Assay- Serum samples from week 3, 4, 5, 6, 7, and 8 were 
analyzed for determination of IgG titers to vaccination of calves with ovalbumin using a 
modified protocol from Rivera et al. (2002). Samples were prepared using a 96-round 
well plate (Immulon 1B, VWR, Radnor, PA). Every other column of the plate was coated 
by pipetting 100 µL of a solution containing 0.005 mg of ovalbumin/mL of PBS or 500 
ng of ovalbumin per well. The non-coated (no ovalbumin) columns served as a control to 
account for non-specific binding. All stock solutions were made fresh the day samples 
were analyzed. Plates were allowed to incubated at 4ºC for at least 12 h (overnight) 
before analysis, to allow adherence of ovalbumin antigen to each coated well. Following 
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overnight incubation plates were emptied and 200 µL of a blocking buffer solution was 
added to each well and allowed to incubate for 1 h at room temperature (~22ºC). The 
blocking solution contained PBST with 2% Casein (Sigma Chemical, St. Louis, MO). 
PBST was prepared as PBS with 0.05% of polyoxeyethylene sorbitan monolaurate 
(Tween 20, Sigma Chemical, St. Louis, MO). Following incubation of the blocking 
buffer, plates were emptied and washed 3 times with PBST and blotted dry. Serum 
samples were thawed and diluted in a two-fold serial dilution with PBST that contained 
0.1% bovine serum albumin (BSA, Sigma Chemical, St. Louis, MO). Dilution of serum 
samples were as followed week 3 (21 d) and 4 (28 d) were diluted 1/4 from initial 
concentration, week 5 (35 d) diluted 1/16, week 6 (42 d) diluted 1/64, week 7 (49 d) and 
8 (56 d) diluted 1/512 from initial concentration. One hundred µL of the diluted samples 
were added to the wells in duplicate and incubated for 1 h at room temperature (~22ºC). 
Following incubation plates were emptied and washed 3 times with PBST wash buffer 
and blotted dry. A second antibody, alkaline phosphatase anti-bovine IgG (Sigma 
Chemical, St. Louis, MO) was diluted to a concentration of 1:5000 in PBST containing 
0.1% BSA and 100 µL was pipetted to each well and incubated for 1 h at room 
temperature (~22ºC). Following incubation plates were emptied and washed 3 times with 
PBST wash buffer and blotted dry. A substrate solution was added at 200 µL per well and 
incubated in the dark at room temperature (~22ºC) for 13 min. Substrate solution was 
made fresh prior to addition to wells and was made by using SIGMAFAST p-nitrophenyl 
phosphate tablets (Sigma Chemical, St. Louis, MO) added to diethanolamine substrate 
buffer (ThermoFisher, Waltham, MA) that was diluted from 5x concentration to 1x with 
distilled water. The reaction was stopped by adding 50 µL of a 2 M NaOH solution to 
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each well. Plates were then read at 405 nm optical wavelength using a 96-well plate 
reader (Biotek, ELx808, Winooski, VT).  
Statistical Analysis 
All data were subjected to least squares ANOVA for a randomized complete 
block design using the PROC MIXED procedure of SAS (version 9.3, SAS Institute Inc., 
Cary, NC). Calves were blocked by birth date. Treatment, week, and treatment x week 
were considered to be fixed effects, with calf within treatment as random effect. Least 
squares means were separated by PDIFF. Body weights, and measurements were adjusted 
by the covariate to account for difference in initial measurements. IgA and IgG titers 
were determined by subtracting control wells (non-coated) from corresponding optical 
density reading for the value of the sample well (coated) to account for non-specific 
binding. Fecal pathogen descriptions were grouped into 1) none detected, 2) rare amount, 
3) small amount, 4) moderate amount, 5) large amount for Escherichia coli and 1) none 
detected, 2) rare/small present, 3) few/moderate present, 4) large/many present for 
Salmonella, Clostridium, and Cryptosporidium. Significance was declared at P < 0.05 
and trends at 0.05 < P < 0.10. Dry matter intake, fecal, nasal, eye, an ear scores were 
averaged by week. Means for the remaining variables were calculated from the data 
gathered during the collection time for each period.  
RESULTS AND DISCUSSION  
Feed Analysis  
Nutrient composition and DM of MR and CS are provided in Table 1. The 20:24 
MR slightly exceeded the for CP formulation specification. However, the fat was slightly 
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below the formulation specification (19.5% compared to 20%) but still is adequate for 
neonatal calves. The CS met or exceed formulation requirements for nutrients.  
Immunological Performances 
 Immunoglobulin A titers were similar (P > 0.10) among all treatments (Table 2 
and Figure 1). However, numerically calves fed EO-0.5 had higher IgA titers compared 
to calves fed the other treatments, and calves fed EO-1.0 and EO-1.5 had the lowest 
titers. 
 Immunoglobulin G titers were similar between treatments for week 3, 4, 5, and 6 
(Table 2 and Figure 2). It was not until the booster ovalbumin vaccine was given during 
week 6 that numerical differences could be observed. Statistically, calves fed EO-1.0 and 
EO-1.5 had the lowest titers compared to calves fed C, EO-0.5 and YCW for weeks 7 and 
8. Similarly to IgA results calves fed EO-0.5 had the highest IgG titer values.   
 Calves fed the EO-0.5 had the greatest immunological response. Too much of an 
immunological response can be detrimental to a growing calf because of the energy 
expenditure needed. However, in this case calves fed EO-0.5 had improved growth rates 
compared to other treatments (Table 5) as well as an improved immunological response, 
indicating that the EO-0.5 improved the immunity of the calves. Calves fed EO-1.0 and 
EO-1.5 had the lowest titer results compared to C, YCW, and EO-0.5 indicating that the 
immune system was possibly overwhelmed and was shut down as a protective response. 
As an overactive immune system response could lead to self-damage from inflammation, 
a properly working immune system can be thought of as a teeter totter. An 
immunological response is great when a challenge arrives but too much of a response will 
result in self-inflicted damages (Mak et al., 2014).    
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Health Performances and Fecal Pathogens 
Total serum blood protein averaged 6.5 ± 0.15 g/dl (Table 3). The mean serum 
protein levels were not different between treatments and were above 5.5 g/dl indicating 
successful passive transfer of immunity. 
Health scores were averaged weekly for the 56 d study (Table 3). Overall health 
scores were acceptable for all calves across all treatments. Fecal scores (Table 3 and 
Figure 3) on weeks one, five, seven, and eight were similar (P > 0.05) for calves fed all 
treatments. Fecal scores were higher on week two for calves fed C compared to calves 
fed EO-1.0, and were significantly greater for calves fed C compared to calves fed EO-
0.5 and YCW on week three. During week four, calves fed EO-1.5 had significantly (P < 
0.05) higher fecal scores compared to calves fed C and EO-0.5. Again on week six fecal 
scores were significantly (P > 0.05) greater for calves fed EO-1.5 compared to calves fed 
EO-1.0. There were some significant differences in nasal, ear, and eye scores (P < 0.05) 
among some treatments, but the differences were small and calves were healthy overall.    
Fecal pathogens were analyzed for samples that were collected on 0, 8, and 35 d 
(Table 4.) Analysis of fecal pathogens indicated no detection of salmonella throughout 
the study with no treatments differences in clostridium and cryptosporidium when the 
calves first arrived for the trial (0 d). Calves fed the control treatment had higher (P < 
0.05) cryptosporidium levels on d 8 compared to calves fed the other treatments, but by d 
35 no difference were observed between treatments. Clostridium was significantly (P < 
0.05) increased for calves fed EO-0.5 compared to calves fed control on 8 d. 
Numerically, by 35 d calves fed EO had lower clostridium levels than calves fed YCW 
and C and EO-1.0 fed calves were significantly (P < 0.05) lower compared to calves fed 
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YCW and C.  Escherichia coli was significantly higher for YCW calves than EO-1.5 fed 
calves on 0 d of the trial but by 8 and 35 d no significant differences were detected.  
Body Growth and Measurements 
Initial, final, and total gains of body weight and body measurements are shown in 
Table 5. The mean initial body weight (BW) of all the calves was 38.9 ± 1.5 kg. Calves 
fed EO-1.0 and EO-1.5 had significantly (P < 0.05) different initial body weights at the 
start of the trial, with no significant (P > 0.10) differences among the other treatments. 
All data were covariate adjusted to minimize pretreatment differences. Total BW gain 
and final BW were increased for calves fed EO-0.5 compared to calves fed EO-1.0, 
YCW, and C. Calves fed EO-0.5 demonstrated greater (P < 0.05) ADG through 56 d 
compared to calves fed EO-1.0 and YCW, while tending (P < 0.10) to be greater for 
calves fed C and EO-1.5. These growth measurements are industry acceptable with calves 
doubling their starting body weight by eight weeks. These growth measurements are also 
exceptional compared to a similar study by Santos et al., (2015) who fed lower amounts 
of EO but similar amounts of MR. In that study, Santos et al., (2015) reported an ADG of 
.38 kg for calves supplemented with a blend of EO (0.4 g/kg).  
Calves fed EO-1.0 had significantly (P < 0.05) greater initial BL and HG 
compared to calves fed C, but similar to calves assigned to the other treatments.  Calves 
fed EO-1.0 had significantly (P < 0.05) greater initial WH compared to calves fed YCW, 
but similar to calves assigned to the other treatments.  Initial HH and HW measurements 
were similar for calves assigned to all treatments. Numerically, by the end of the study, 
calves fed EO-0.5 had the greatest body measurement gains. Calves fed EO-0.5 were 
significantly (P < 0.02) greater than calves fed EO-1.5 in BL gains.  Gains in HW were 
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greater for calves fed EO-0.5 compared to calves fed C, but were similar among the 
remaining treatments. Gains of WH through 56 d was greater for calves fed EO-0.5 
compared to calves C, EO-1.0, EO-1.5, while being similar for calves fed YCW. Gains in 
HH were greater for calves fed EO-0.5 compared to calves fed C, EO-1.0, EO-1.5 and 
YCW.  Gains in HG calves fed C were significantly increased compared to calves fed 
YCW, however, calves fed EO-0.5 had the highest numerical HG gains while calves fed 
EO-1.5 had the lowest numerical gains. The reasons for these values not showing up 
significantly different is attributed to the standard errors of the samples being less than 
that of the other treatments.  This data demonstrates that feeding EO-0.5 (1.25 g/calf/d) to 
a 24:20 MR will enhance growth rates compared to calves fed a modified accelerated 
24:20 MR and a 24:20 MR containing YCW technology. 
Volatile Fatty Acids  
 Serum blood samples from week five were analyzed for volatile fatty acids (VFA) 
as an indirect measurement of rumen development (Table 6). Quigley et. al., (1990) 
found that differences in plasma VFA were greatest between five and eight weeks of age 
in calves that were weaned early (28 d) and late weaned calves (56 d). Week five was the 
start of weaning and the blood VFA concentrations were similar between all treatments. 
Blood concentrations of isobutyrate and valerate were below detection limits. There was 
no significant difference (P > 0.10) in propionate and butyrate concentrations between 
treatments. These results are similar to data reported by Santos et al., (2015) who found 
no significant differences in propionate, butyrate, and acetate in calves supplemented 
with and without EO. Calves fed YCW were significantly lower in acetate concentration 
compared to calves fed C, EO-0.5, EO-1.0, and EO-1.5. Calves fed YCW were 
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significantly lower in isovalerate concentration compared to calves fed EO-1.0 and EO-
1.5, but were similar in concentration to C and EO-0.5 calves. The VFAs are known to 
initiate epithelial and papillary growth within the rumen and butyrate is considered the 
most effective followed by propionate and acetate (Sakate and Tamate, 1979). Based on 
this knowledge it can be concluded that the treatments in this study neither inhibited nor 
enhanced ruminal development. 
Dry matter intake, feed efficiency 
 Calf starter intake on a dry matter basis had no significant (P > 0.10) differences 
among treatments during the initial four weeks (Figure 5 and Table 7). The start of 
weaning (week five) calves fed EO-0.5 had significantly (P < 0.05) greater CS 
consumption than calves fed YCW, which continued through week 7 and 8. During week 
six, calves fed EO-1.0 had significantly greater CS intake compared to calves fed YCW, 
while calves fed EO-0.5 had greater CS intake compared to calves fed C and YCW. Total 
dry matter intake (MR plus CS) yielded similar results as CS DMI (Table 7). There were 
no significant (P > 0.10) differences in gain per feed (feed efficiency) among the 
different treatments (Table 7). Similar studies supplementing calves with EO have 
reported varying results. In a study conducted by Santos et al., (2015) found that calves 
supplemented with a blend of EO were similar in CS intake compared to non-
supplemented calves. However, these results are in contrast to data reported by Hill et al., 
(2007) that demonstrated a commercial blend of EO actually increased CS intake and 
efficiency. 
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CONCLUSIONS 
 In this study the hypothesize proved partly true. Dairy calves supplemented with a 
commercial EO performed well compared to non-supplemented calves. However, dairy 
calves fed EO-0.5 demonstrated the optimal response compared to the hypothesized EO-
1.0. Body weight, measurements, and ADG gains were numerically higher for EO-0.5 
then calves fed C, YCW, and higher doses of essential oils. Similarly, calves fed EO-0.5 
had the highest numerical IgA and IgG titers corresponding well with growth 
performance data indicating healthier calves. Calves fed EO-0.5 compared to C calves 
had significantly higher HG, WH, HH, WH, and BW gains. Furthermore, blood VFA 
concentrations were similar among treatments, indicating that the EO neither inhibited 
nor enhanced ruminal development. Health scores among treatments were acceptable and 
calves supplemented with EO were neither healthier or sicker compared to calves fed the 
other treatments. In some weeks, calves supplemented with EO numerically had 
improved fecal scores compared to calves fed C and YCW.  
 Overall, calves benefit with supplementation of a commercial EO. Questions still 
remain and future direction would be to see if a different dosage of this commercial EO 
could improve immunological, and growth of calves even more either through a lower 
dose or possibly a slightly higher (but lower than EO-1.0) dose. Other potential options 
would be to see if there is any benefit of feeding EO in the solid feed (pellets) of calves 
for an extended period of time that would extend past weaning.   
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Table 1. Milk replacer and calf starter nutrient analysis 
 
Item1 Milk Replacer Calf Starter 
DM, % 95.6 87.3 
Crude Protein, % 26.0 23.5 
ADF, % 0.93 12.0 
Fat, % 19.5 3.3 
Starch, % 0.93 21.5 
Ash, % 9.87 7.5 
Calcium, % 0.94 0.85 
Phosphorus, % 0.72 0.61 
Magnesium, % 0.14 0.38 
Mcal, kcal/kg 2730.9 2097.3 
1Nutrient analysis conducted by Analabs (Fulton, IL). Values are reported as % DM.  
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Table 2. Immunological titers 
 Treatments1  
Item C EO-0.5 EO-1.0 EO-1.5 YCW SEM 
No. calves 20 20 20 19 20  
IgA       
0 d 8.2 7.7 2.8 4.6 5.3 4.1 
21 d 17.3 26.5 17.1 19.9 17.9 4.6 
IgG       
21 d 10.1 7.5 7.3 10.2 5.7 597.0 
28 d 30.8 10.3 19.9 7.3 9.4 597.0 
35 d 178.1 141.3 166.7 78.9 142.6 613.3 
42 d 411.2 441.0 405.4 270.9 405.9 597.0 
49 d 4536.4ac 5058.5ac 2602.6bc 1956.8b 4037.0ac 597.0 
56 d 4224.7ab 5310.0ab 2339.6c 2192.1c 3684.2b 597.0 
1Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g Stay Strong 
added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g Bio-Moss added. All MR 
were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then fed 1x/d from 36 d to weaning at 42 
d.  
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Table 3. Total serum proteins and health scores 
Treatments1 
Item C EO-0.5 EO-1.0 EO-1.5 YCW SEM 
No. calves 20 20 20 19 20  
Serum Protein 6.40 6.50 6.56 6.43 6.62 0.21 
Fecal Scores2       
1 to 7 d 1.09 1.19 1.22 1.27 1.18 0.08 
8 to 14 d 2.01a 1.83ab 1.75b 1.84ab 1.93ab 0.08 
15 to 21 d 1.28a 0.97bc 1.05abc 1.13abc 1.08bc 0.08 
22 to 28 d 0.33b 0.38b 0.45ab 0.58a 0.40ab 0.08 
29 to 35 d 0.21 0.20 0.23 0.24 0.24 0.08 
36 to 42 d 0.19ab 0.15ab 0.05b 0.28a 0.09ab 0.08 
43 to 49 d 0.10 0.07 0.06 0.005 0.09 0.08 
50 to 56 d 0.05 0.03 0.03 0.03 0.02 0.08 
Nasal Scores3       
1 to 7 d 0.05 0.06 0.06 0.07 0.05 0.02 
8 to 14 d 0.01b 0.01b 0.05b 0.14a 0.02b 0.02 
15 to 21 d 0 0.01 0.03 0.05 0.03 0.02 
22 to 28 d 0b 0.07a 0.07a 0.05ab 0.06ab 0.02 
29 to 35 d 0.02 0.06 0.03 0.01 0.03 0.02 
36 to 42 d 0 0.03 0.02 0.04 0.01 0.02 
43 to 49 d 0.07 0.01 0.02 0.06 0.04 0.02 
50 to 56 d 0.01b 0.02b 0.03ab 0.08a 0.01b 0.02 
Eye Scores4       
1 to 7 d 0.03 0.04 0.08 0.10 0.04 0.05 
8 to 14 d 0.06 0.06 0.06 0.07 0.10 0.05 
15 to 21 d 0.26 0.18 0.27 0.29 0.30 0.05 
22 to 28 d 0.31a 0.15b 0.21ab 0.22ab 0.24ab 0.05 
29 to 35 d 0.17b 0.19b 0.35a 0.23ab 0.14ab 0.05 
36 to 42 d 0.18ab 0.18ab 0.27a 0.19ab 0.12b 0.05 
43 to 49 d 0.17 0.20 0.17 0.18 0.27 0.05 
50 to 56 d 0.25 0.23 0.27 0.27 0.24 0.05 
Ear Scores5       
1 to 7 d 0.42bc 0.42bc 0.53abc 0.59ac 0.61a 0.06 
8 to 14 d 0.75 0.63 0.59 0.61 0.65 0.06 
15 to 21 d 0.65 0.63 0.65 0.71 0.58 0.06 
22 to 28 d 0.68a 0.67a 0.61ab 0.44b 0.61ab 0.06 
29 to 35 d 0.67a 0.43b 0.62a 0.46b 0.53ab 0.06 
36 to 42 d 0.47 0.42 0.43 0.51 0.58 0.06 
43 to 49 d 0.41 0.39 0.47 0.42 0.37 0.06 
50 to 56 d 0.37 0.31 0.28 0.24 0.41 0.06 
1Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g Stay 
Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g Bio-Moss added. 
All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then fed 1x/d from 36 d to 
weaning at 42 d.  
2 Fecal score = 0 to 3; 0 = normal, ≥ 2 = scours  
3Nasal score = 0 to 3; 0 = normal, 3 = excessive mucopurulent discharge 
4Eye score = 0 to 3; 0 = normal, 3 = heavy ocular discharge 
5Ear score = 0 to 3; 0 = normal, 3 = droopy 
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Table 4. Fecal pathogens 
 
 Treatments1  
Item C EO-0.5 EO-1.0 EO-1.5 YCW SEM 
No. calves 20 20 20 19 20 --- 
Escherichia coli2       
0 d 4.3ab 4.2ab 4.3ab 4.0b 4.5a 0.3 
8 d 3.8 3.9 3.8 3.8 4.1 0.5 
35 d 3.8 3.1 3.2 3.1 3.1 0.4 
Salmonella3       
0 d ND ND ND ND ND --- 
8 d ND ND ND ND ND --- 
35 d ND ND ND ND ND --- 
Clostridium4       
0 d 1.4 1.6 1.7 1.5 1.6 0.3 
8 d 1.0b 1.4a 1.4ab 1.2a 1.3ab 0.2 
35 d 1.3a 1.2ab 1.1b 1.2ab 1.4a 0.2 
Cryptosporidium5       
0 d 1.0 1.1 1.0 1.0 1.0 0.0 
8 d 2.2a 1.8ab 1.5ab 1.5ab 1.6b 0.4 
35 d 1.0 1.1 1.1 1.0 1.1 0.1 
1Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g Stay Strong 
added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g Bio-Moss added. All MR 
were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then fed 1x/d from 36 d to weaning at 
42 d.  
2Escherichia coli = 1 to 5; 1 = absent, 5 = large amount present 
3Salmonella = 1 to 4; 1 = absent, 4 = large amount present 
4Clostridium = 1 to 4; 1 = absent, 4 = large amount present 
5Cryptosporidium = 1 to 4; 1 = absent, 4 = large amount present  
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Table 5. Body weight, measurements, ADG 
 
Treatments1 
Item C EO-0.5 EO-1.0 EO-1.5 YCW SEM 
No. calves 20 20 20 19 20  
BW, kg       
Initial 38.1ab 39.2ab 41.1a 37.0b 38.9ab 3.4 
Final  75.7b 79.2a 72.1b 74.7ab 74.4b 6.4 
Gain 36.8b 39.9a 35.5b 35.8ab 35.4b 6.4 
ADG, kg 0.65ab 0.71a 0.64b 0.64ab 0.63b 0.08 
BL, cm       
Initial 62.52b 63.99ab 64.49a 63.47ab 62.77ab 1.09 
Final 76.62ab 78.16a 76.58ab 75.63b 76.67ab 1.06 
Gain 13.11ab 14.66a 13.08ab 12.12b 13.17ab 1.06 
HG, cm       
Initial 77.10b 79.48ab 80.26a 77.74ab 79.0ab 1.20 
Final 98.12b 98.45ab 96.52bc 96.42bc 96.57c 0.80 
Gain 19.30b 19.68ab 17.70bc 17.60bc 17.75c 0.80 
WH, cm       
Initial 75.43ab 76.08ab 77.09a 74.96ab 74.89b 1.03 
Final 85.56b 87.13a 85.58b 85.18b 86.15ab 0.54 
Gain 9.78b 11.34a 9.80b 9.40b 10.36ab 0.54 
HH, cm       
Initial 79.87 80.21 81.98 79.75 79.73 1.02 
Final 90.58b 92.58a 90.0b 90.20b 90.97b 0.73 
Gain 10.13b 12.13a 9.56b 9.77b 10.52b 0.73 
HW, cm       
Initial 46.29 47.31 47.47 46.71 46.92 1.57 
Final  69.18b 71.76a 69.62ab 69.38ab 69.47ab 1.52 
Gain 22.18b 24.76a 22.62ab 22.38ab 22.47ab 1.52 
1
Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g 
Stay Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g 
Bio-Moss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR 
then fed 1x/d from 36 d to weaning at 42 d.  
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Table 6. Volatile Fatty Acids 
 
 Treatments1  
Item C EO-0.5 EO-1.0 EO-1.5 YCW SEM 
Acetate, mM 0.64a 0.61a 0.60a 0.61a 0.48b 0.06 
Propionate, mM 0.05 0.04 0.07 0.06 0.03 0.01 
Isobutyrate, mM ND ND ND ND ND  
Butyrate, mM 0.06 0.07 0.07 0.06 0.06 0.01 
Isovalerate, mM 0.002ab 0.004ab 0.006a 0.007a 0.001b 0.002 
Valerate, mM ND ND ND ND ND  
1
 Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g Stay Strong added; EO-1.5: 24:20 MR with 3.75 g 
Stay Strong added; YCW: 24:20 MR with 2 g Bio-Moss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then fed 
1x/d from 36 d to weaning at 42 d.  
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Table 7. CS DMI, Total DMI, Gain per Feed 
 Treatments1  
Item C EO-0.5 EO-1.0 EO-1.5 YCW SEM 
No. calves 20 20 20 19 20  
CS DMI, kg/d       
1 to 7 d 0.02 0.01 0.01 0.02 0.01 0.08 
8 to 14 d 0.05 0.05 0.05 0.05 0.02 0.08 
15 to 21 d 0.13 0.18 0.16 0.18 0.12 0.08 
22 to 28 d 0.29 0.33 0.28 0.33 0.27 0.08 
29 to 35 d 0.46ab 0.58a 0.54ab 0.52ab 0.41b 0.08 
36 to 42 d 0.97bc 1.17ac 1.07ac 1.04abc 0.90b 0.08 
43 to 49 d 1.84ab 1.90a 1.86ab 1.87ab 1.73b 0.08 
50 to 56 d 2.25ab 2.31a 2.17ab 2.19ab 2.14b 0.08 
Total DMI, 
kg/d 
      
1 to 7 d 0.55 0.55 0.55 0.55 0.55 0.08 
8 to 14 d 0.58 0.59 0.58 0.59 0.56 0.08 
15 to 21 d 0.95 1.00 0.98 1.00 0.94 0.08 
22 to 28 d 1.11 1.15 1.10 1.16 1.09 0.08 
29 to 35 d 1.27ab 1.40a 1.36ab 1.34ab 1.23b 0.08 
36 to 42 d 1.38bc 1.58a 1.48ab 1.45abc 1.31c 0.08 
43 to 49 d 1.85ab 1.90a 1.86ab 1.87ab 1.73b 0.08 
50 to 56 d 2.25ab 2.31a 2.17ab 2.19ab 2.14b 0.08 
Gain per Feed       
1 to 7 d 0.90 0.94 0.91 0.92 0.88 0.11 
8 to 14 d 0.19 0.30 0.09 0.33 0.12 0.11 
15 to 21 d 0.76 0.81 0.70 0.72 0.73 0.11 
22 to 28 d 0.56 0.63 0.64 0.61 0.70 0.11 
29 to 35 d 0.70 0.63 0.64 0.57 0.55 0.11 
36 to 42 d 0.34 0.50 0.40 0.38 0.39 0.11 
43 to 49 d 0.42 0.38 0.44 0.39 0.41 0.11 
50 to 56 d 0.49 0.47 0.44 0.41 0.53 0.11 
1Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g 
Stay Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g Bio-
Moss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then 
fed 1x/d from 36 d to weaning at 42 d.  
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Figure 1. IgA titers 
Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g 
Stay Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g Bio-
Moss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then 
fed 1x/d from 36 d to weaning at 42 d.  
 
47 
 
 
  
0.0
1,000.0
2,000.0
3,000.0
4,000.0
5,000.0
6,000.0
3 4 5 6 7 8
A
n
ti
b
o
d
y
 T
it
er
Week
Control EO 0.5 EO 1.0 EO 1.5 YCW
Figure 2. IgG titers 
Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g 
Stay Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g Bio-
Moss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then 
fed 1x/d from 36 d to weaning at 42 d.  
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Figure 3. Fecal scores 
Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g 
Stay Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g Bio-
Moss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then 
fed 1x/d from 36 d to weaning at 42 d.  
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Figure 4. Body weight 
Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g 
Stay Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g Bio-
Moss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then 
fed 1x/d from 36 d to weaning at 42 d.  
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Figure 5. Calf starter intake 
Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g 
Stay Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g Bio-
Moss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then 
fed 1x/d from 36 d to weaning at 42 d.  
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